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Abstract
Background: Several studies have shown an association between vitamin D deficiency and cardiovascular risk. Vitamin D
status is assessed by determination of 25-hydroxyvitamin D [25(OH)D] in serum.
Methods: We assessed the prognostic utility of 25(OH)D in 982 chest-pain patients with suspected acute coronary
syndrome (ACS) from Salta, Northern Argentina. 2-year follow-up data including all-cause mortality, cardiac death and
sudden cardiac death were analyzed in quartiles of 25(OH)D, applying univariate and multivariate analysis.
Results: There were statistically significant changes in seasonal 25(OH)D levels. At follow-up, 119 patients had died. The
mean 25(OH)D levels were significantly lower among patients dying than in long-term survivors, both in the total
population and in patients with a troponin T (TnT) release (n = 388). When comparing 25(OH)D in the highest quartile to the
lowest quartile in a multivariable Cox regression model for all-cause mortality, the hazard ratio (HR) for cardiac death and
sudden cardiac death in the total population was 0.37 (95% CI, 0.19–0.73), p = 0.004, 0.23 (95% CI, 0.08–0.67), p = 0.007, and
0.32 (95% CI, 0.11–0.94), p = 0.038, respectively. In patients with TnT release, the respective HR was 0.24 (95% CI, 0.10–0.54),
p = 0.001, 0.18 (95% CI, 0.05–0.60), p = 0.006 and 0.25 (95% CI, 0.07–0.89), p = 0.033. 25(OH)D had no prognostic value in
patients with no TnT release.
Conclusion: Vitamin D was shown to be a useful biomarker for prediction of mortality when obtained at admission in chest
pain patients with suspected ACS.
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Introduction
It is well known that Vitamin D deficiency in humans is
widespread and increasing [1]. Vitamin D can be ingested or
created in the skin on exposure to sun and is essentially derived
from the latter source. Vitamin D status is commonly assessed by
determination of 25-hydroxyvitamin D [25(OH)D] in serum [2].
Optimal and exact cut-off levels of 25(OH)D are still under
debate. The following cut-off levels have been recognized; normal
values 75–250 nmol/L, insufficiency 50–74 nmol/L and deficien-
cy ,50 nmol/L [3–4]. However, these values are based on
registry data which do not fully take into account population and
geographical differences, and factors such as gender and genetics
[1].
Several observational studies and epidemiological data suggest
that low levels of 25(OH)D may be related to mortality and
cardiovascular disease (CVD) [5–12] such as myocardial infarction
(MI) [13–14] and sudden cardiac death (SCD) [15].
The general diet does not contain a sufficient amount of vitamin
D and without supplementation we depend on sun exposure to
obtain a satisfactory level of this vitamin. The cutaneous synthesis
of vitamin D is influenced by several factors, including geograph-
ical location, latitude, altitude, season and daytime, the color of the
skin, age and obesity [3,16–17].
Fish, the main diet source of vitamin D, is less preferred by the
inland and highland beef-consuming population in Northern
Argentina, resulting in a lower dietary intake of vitamin D. In our
study population from Salta, Argentina, dietary insufficiency of
vitamin D may be outweighed by the increased sun exposure
through the entire year at this latitude (24 degrees south of the
Equator) and an altitude above 1000 m. Therefore, we have
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assumed that sun exposure may be the essential energy source for
the production of vitamin D synthesis in this population.
Thus, the purpose of this study was to assess the prognostic
utility of 25(OH)D in 982 chest-pain patients with suspected acute
coronary syndrome (ACS) living within the described area of
Argentina.
Methods
Ethics Statement
The study was approved by the Ethics Committee at the Board
of Medical School of Salta and conducted in accordance with the
Helsinki Declaration of 1971, as revised in 1983. At San Bernardo
Hospital and Sanatorio El Carmen, the study was also approved
by the local Ethics Committee and Institutional Review Board of
San Bernardo Hospital and the Institutional Review Board of
Sanatorio El Carmen, respectively. The Norwegian biobank
containing Argentinean blood samples was approved by the
Regional Board of Research Ethics and the Norwegian health
authorities. This study was monitored by Stavanger Health
Research, Stavanger, Norway. Written informed consent was
obtained from all patients.
Study Design and Patient Population
This study was performed at nine hospitals in the Province of
Salta, Northern Argentina and was given the acronym ARRA-
RACS (ARgentinean Risk Assessment Registry in the Acute
Coronary Syndrome), registered in ClinicalTrials.gov Identifier
NCT01377402. It was designed to evaluate the prognostic utility
of serum 25(OH)D (D represents D2 and D3) status in 982 patients,
hospitalized consecutively with chest pain and a suspected ACS,
from December 2005 to January 2009. The patients had to be
above 18 years of age and willing to participate in this study after
informed consent. Eight centers were private and one was public.
The latter included sixty-two (6.5%) of the patient population.
The primary outcome was 2-year all-cause mortality from the
time of inclusion and the secondary outcomes included cardiac
death and sudden cardiac death.
During the two year follow-up period, the participants were
interviewed by telephone at 30 days, 6 and 24 months, and they
were invited for a physical examination at 12 months. Family,
neighbours and the national registry department were contacted to
obtain relevant information regarding relocations. Information
related to cause of death was obtained through official records and
additional information was supplied by close family members.
Clinical parameters based on hospital records and personal
interviews included age, gender, assessment of previous MI,
angina pectoris, previous revascularizations [percutaneous coro-
nary intervention (PCI) or coronary artery bypass graft (CABG)],
congestive heart failure (CHF) according to Killip-Kimball class
[18], diabetes mellitus (DM), smoking status (categorized as
current smokers, previous smokers or never-smokers), hypercho-
lesterolemia (defined as total cholesterol concentrations above
250 mg/dl or statin treatment), beta-blocker use, arterial hyper-
tension (defined as repeated blood pressure measurements above
140/90 mmHg or treated hypertension), body mass index (BMI)
(kg/m2) and month of sample collection. Electrocardiographic
findings at admission were classified according to the presence of
ST-segment changes (i.e. ST-segment depression or elevation, T-
wave inversion or left bundle-branch block).
Blood samples for determination of laboratory parameters were
obtained at admission. A second blood sample for repeated
troponin T (TnT) determination was drawn 6 hours following the
primary blood sample. Baseline data included 25(OH)D2 and
25(OH)D3, TnT, high sensitivity C-reactive protein (hsCRP),
glucose, serum lipids, B-type natriuretic peptide (BNP) measured
in EDTA (ethylene diamine tetraacetic acid) plasma, and
estimated glomerular filtration rate (eGFR), [calculated by
Modification in Diet in Renal Disease (MDRD) formula].
The term ACS in this study included unstable angina pectoris,
non ST-segment elevation myocardial infarction (NSTEMI) and
ST-segment elevation myocardial infarction (STEMI), as previ-
ously described [19].
The definition of cardiac death included death preceded by a
definitive MI or by chest pain .20 minutes without a given TnT,
or a history of ischemic heart disease and no other obvious cause
of death [20]. SCD is defined as unexpected death due to a cardiac
cause occurring within one hour of symptom onset or as a
witnessed unexpected death [21].
Furthermore, the total patient population was divided into two
subgroups, with and without TnT release, respectively.
Blood Sampling Procedures and Laboratory
Measurements
Blood samples were drawn immediately following admission in
a nonfasting state by direct venipuncture of an antecubital vein,
applying minimum stasis. Clotted whole blood and EDTA blood
samples were centrifuged for 15 min with 20006 g at 20uC
without delay. Serum and EDTA plasma were frozen in three
aliquots, stored locally at 270uC and transferred in frozen
condition (dry ice) to Stavanger, Norway in three different
shipments; after collection of the first 100 samples, the next 400
samples and finally the remaining samples, respectively. These
samples were stored in the Norwegian biobank at 270uC.
Assessment of vitamin D status was performed by determination
of the metabolites 25(OH)D3 and 25(OH)D2 in serum by liquid-
liquid extraction (LLE), derivatization with 4-phenyl-1,2,4-triazo-
line-3,5-dione reagent (PTAD, Sigma-Aldrich, St. Louis, MO,
USA), and analysis by liquid chromatography coupled with
tandem mass spectrometry detection (LC-MS/MS). A one-step
LLE procedure was performed by mixing 50 ml serum, 50 ml
internal standard solution, comprising 160 ng/ml of 6-deuterium
labeled 25(OH)D3 (Synthetica, Oslo, Norway) in isopropanol,
350 ml of 200 mmol/L magnesium sulphate, and finally 900 ml
acetone and heptane (1+1). The upper heptane layer was acquired
and evaporated, followed by addition of 100 ml of 0.5 mg/ml
PTAD reagent in dry acetonitrile. The LC-MS/MS analysis was
performed with an Acquity UPLC coupled with a Quattro Micro
(Waters, Milford Massachusetts, USA). The separation was
isocratic, using a 2.1650 mm Acquity BEH C18 UPLC column
(Waters) and a 0.5 mL/min mobile phase flow consisting of 20%
ammonium hydroxide (0.1%) and 80% acetonitrile. Tandem mass
spectrometry detection was with positive electrospray ionization
(ESI+), using 3 kV and 30 V for capillary and cone voltage,
respectively. Collision energies were 15 for 25(OH)D3 and 17 for
25(OH)D2. The multiple reaction monitoring transitions were
558.5.298.2 for 25(OH)D3, 564.5.298.2 for deuterium labeled
25(OH)D3, and 570.5.298.2 for 25(OH)D2.
Calibration was achieved by using serum calibrator #38033
(Chromsystems, Munich, Germany). With each microwell plate,
the analytical quality was monitored by analysis of 5 different
control samples: #0029 and #0030 (Chromsystems), #35080 and
#35081 (Recipe, Munich, Germany), and HK10 (DEKS, Herlev,
Denmark). The coefficients of variation (CV) for the control
samples analyzed over 25 series were in the range of 8.7–10.8%
for 25(OH)D3 and in the range of 10.7–16.5% for 25(OH)D2.
Intra-series repeatability was estimated at three different levels,
and CV’s found in the range of 2.9–8.2%. Method bias was
Vitamin D, a Predictor of Mortality in ACS
PLOS ONE | www.plosone.org 2 September 2012 | Volume 7 | Issue 9 | e43228
estimated by relative difference from the quality control sample
values. For 25(OH)D3, 21–22% bias was found by analysis of
control samples with a reference value of 38.6 and 59 nmol/L,
and 1–2% bias was found for samples with a reference value of
73.4 and 136 nmol/L. For a control sample with a high reference
value of 265 nmol/L, the bias was 218%. For 25(OH)D2, control
samples with reference values of 39, 62 and 126 nmol/L,
respectively, were associated with a bias in the range of 23 to
8%, and 29% for a sample with a high reference value of
252 nmol/L.
TnT was quantified by a cardiac-specific second-generation
TnT ELISA assay from Roche diagnostics, using a high-affinity
cardiac-specific TnT isoform antibody [22]. The lower detection
limit of the assay used is 0.01 ng/mL. In this study a cut-off level
of 0.05 ng/mL was used with a CV of 10% for the diagnosis of a
MI, whereas patient groups in this study were defined according to
TnT release (TnT.0.01 ng/ml).
BNP (Microparticle Enzyme Immunoassay Abbott AxSYMH
(Abbott Laboratories, Abbott Park, Illinois, USA) and hsCRP
[Tina-quantH C-reactive protein (latex) high sensitive assay, Roche
Diagnostics, Germany] were analyzed as recommended by the
manufacturer, and as previously described [19].
Statistical Analysis
Patients were divided into quartiles according to their 25(OH)D
levels. Approximately normally distributed variables were given as
mean and standard deviation (SD). The Chi-square test for
association was applied between the 25(OH)D quartiles and
categorical variables at baseline. The one way ANOVA was used
to test for equality of means of scale variables (e.g. age) amongst
25(OH)D quartiles. The hazard ratios (HR) are presented with
95% confidence interval (CI). Stepwise Cox multivariable
proportional hazards regression models with total death, cardiac
death and SCD as the dependent variable, and 25(OH)D and
other variables as potential independent predictors (listed below)
were fitted. To examine the differences in prognosis between
subjects in the upper quartiles versus the lowest quartile of
25(OH)D, we adjusted for gender, age, smoking, hypertension,
index diagnosis, DM, CHF (defined as Killip-Kimball class at
admission; patients in class 2 to 4 were classified as CHF patients
and patients in class 1 were classified as non CHF), history of
previous CHD (i.e. history of either angina pectoris, MI, CABG,
or PCI), hypercholesterolemia/use of statins, TnT.0.01 ng/mL,
eGFR, hsCRP, BNP, BMI, months of the year and beta-blockers
prior to enrolment. The Kaplan-Meier product limits were used
for plotting the times to event with the equality of the 25(OH)D
quartile survival curves assessed by the log-rank test.
In the discriminate analysis 25(OH)D and its natural logarithm
were used as individual variables. The statistical analyses were
performed using the statistical package SPSS version 19.0. All tests
were two-sided with a significance level of 5%.
Results
A total of 982 patients (588 men and 394 women) were enrolled
in the ARRA-RACS study. Two samples were not available and
four patients were lost to follow up. Thus 976 patients were left for
the analysis of 25(OH)D as a predictor of outcome in our chest
pain population. At index hospitalization, 388 patients (39.6%)
had a peak TnT concentration exceeding 0.01 ng/mL. Mean age
in the total population was 62.2613.4 years.
The baseline characteristics, according to 25(OH)D quartiles at
admission in all patients and in patients with TnT release, are
shown in Table 1 and 2, respectively.
Table 1. Baseline characteristics of the total population
arranged according to the quartiles of 25(OH)D.
Quartiles of 25(OH)D
Characteristics
n (%) Q1 Q2 Q3 Q4 p-value
25(OH)D (nmol/L)* 30.765.6 44.663.7 56.363.4 72.9611.1 ,0.0001
Age, years* 68.6612.5 62.8612.2 59.3613.7 57.9612.6 ,0.0001
Male, n (%) 106 (43.3) 138 (56.6) 171 (69.5) 172 (70.2) ,0.0001
Smoking status, n
(%)
0.383
Current Smoker,
n (%)
53 (22.2) 61 (25.7) 62 (25.5) 61 (25.3)
Past smoker,
n (%)
148 (61.9) 132 (55.7) 126 (51.9) 130 (53.9)
Never Smoked,
n (%)
38 (15.9) 44 (18.6) 55 (22.6) 50 (20.7)
Angina Pectoris, n
(%)
46 (18.8) 61 (25.0) 68 (27.6) 48 (19.6) 0.054
CHF, n (%)
Killip Class 2–4 59 (24.1) 33 (13.5) 29 (11.8) 44 (18.0) 0.001
History of previous
MI, n (%)
28 (11.4) 23(9.4) 23 (9.3) 20 (8.2) 0.670
CABG, n (%) 9 (3.7) 17 (7.1) 12 (4.9) 9 (3.7) 0.275
PCI, n (%) 25 (10.2) 20 (8.2) 28 (11.4) 25 (10.2) 0.699
Hypertension,
n (%)
178 (72.7) 159 (65.2) 143 (58.1) 153 (62.4) 0.007
History of DM 1,
n (%)
7 (2.9) 6 (2.5) 2 (0.8) 0 (0.0) 0.029
History of DM 2,
n (%)
72 (30.0) 49 (20.3) 38 (15.6) 28 (11.6) ,0.0001
STEMI, n (%) 34 (14.2) 35 (14.8) 29 (11.9) 46 (18.9) 0.181
TnT release, n (%) 116 (47.3) 89 (36.5) 90 (36.7) 93 (38.0) 0.041
eGFR (mmol L21)* 77.8632.5 82.7629.4 84.6625.9 80.0625.1 0.041
Cholesterol/Statin,
n (%)
41 (16.7) 40 (16.4) 39 (15.9) 39 (15.9) 0.993
Beta-blocker, n (%) 59 (24.5) 69 (28.6) 63 (25.9) 62 (25.7) 0.767
Known CHD, n (%) 71 (29.3) 89 (36.8) 91(37.1) 73 (29.9) 0.116
BMI (kg/m2)* 28.265.0 27.865.0 28.664.0 27.863.6 0.202
BNP Quartiles ,0.0001
Q1 52 (21.2) 53 (21.7) 73 (29.7) 67 (27.3)
Q2 46 (18.8) 65 (26.6) 62 (25.2) 72 (29.4)
Q3 54 (22.0) 66 (27.0) 66 (26.8) 59 (24.1)
Q4 93 (38.0) 60 (24.6) 45 (18.3) 47 (19.2)
hsCRP Quartiles 0.001
Q1 42 (17.3) 61 (25.1) 65 (26.4) 76 (31.0)
Q2 58 (23.9) 55 (22.6) 73 (29.7) 61 (24.9)
Q3 59 (24.3) 73 (30.0) 56 (22.8) 56 (22.9)
Q4 84 (34.6) 54 (22.2) 52 (21.1) 52 (21.2)
*Mean 6 SD.
SD, standard deviation; 25(OH)D, 25-hydroxyvitamin D; CHF, congestive heart
failure; MI, myocardial infarction; CABG, coronary artery bypass grafting; PCI,
percutaneous coronary intervention; DM, diabetes mellitus; STEMI, ST-elevation
myocardial infarction; TnT, troponin T; eGFR, estimated glomerular filtration
rate; CHD, coronary heart disease; BMI, body mass index; BNP, B-type natriuretic
peptide; hsCRP, high sensitivity C-reactive protein.
doi:10.1371/journal.pone.0043228.t001
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In the total population there was a significant and gradual
decrease in age from the lowest (Q1) to the highest quartile (Q4) of
25(OH)D and a higher proportion of patients with a TnT
exceeding 0.01 ng/mL was noted in Q1 as compared to higher
quartiles. In addition, more patients with hypertension, DM type 1
and 2 and heart failure, were found in Q1. The lowest quartile also
had higher levels of BNP, hsCRP and lower levels of eGFR.
Similar differences (except for hypertension, eGFR and hsCRP)
were found in patients with a TnT release. Moreover, in the latter
subpopulation more CHD patients were found in the higher
quartiles as compared to Q1.
The variations in 25(OH)D by month are shown in Figure 1 and
significant seasonal changes in serum 25(OH)D levels were found.
The mean 25(OH)D value was 54.1 nmol/L (95% CI, 52.6 nmol/
L–55.5 nmol/L) between October and March, and 48.3 nmol/L
(95%CI, 46.9 nmol/L–49.8 nmol/L) between April and Septem-
ber; p,0.0001.
A significantly higher proportion of patients dying was found in
Q1 of 25(OH)D as compared to Q4, both in the total population
(25.3% vs 6.1%) and in patients with a TnT release, (43.3% vs
9.3%) each p,0.0001, respectively.
25(OH)D status and loge (25(OH)D) were used as individual
variables in a discriminate analysis (Table 3) with the purpose to
predict fatal outcome in the total population and in patient groups
with and without TnT release, respectively. The specificity of non-
logarithmic 25(OH)D for predicting all-cause mortality in the total
population was 62.2%, with a sensitivity of 67.2%.
Total Patient Population
All-cause mortality, cardiac death and sudden cardiac
death. After a follow-up period of 24 months, 119 patients
(12.2%) had died. In 66 patients (6.9%) death was defined as
cardiac, of which 50 patients (5.3%) were characterized as SCD.
Kaplan-Meier survival curves for all-cause mortality in the
25(OH)D quartiles at baseline for all patients are presented in
Figure 2.
Receiver operated characteristics (ROC) curve for 25(OH)D for
all-cause mortality is shown in Figure 3. The area under the ROC
for 25(OH)D was 0.307 (p,0.0001).
In the univariate Cox regression analysis there was a statistically
highly significant difference between each of the upper three
quartiles’ HR as compared to Q1 of 25(OH)D in the total patient
population with respect to all-cause mortality, cardiac death and
SCD.
When comparing 25(OH)D in Q4 to Q1 in a multivariable Cox
regression model for all-cause mortality within 2 years in the total
patient population, the HR was 0.37 (95% CI, 0.19–0.73),
p = 0.004. For cardiac death, the HR was 0.23 (95% CI, 0.08–
0.67), p = 0.007, and for SCD the HR was 0.32 (95% CI, 0.11–
0.94), p = 0.038 (Table 4).
Patients with troponin T release
All-cause mortality, cardiac death and sudden cardiac
death. In the 388 patients admitted with TnT release we found
that 82 patients (21.2%) had died during the 2-year follow-up.
Death was categorized as cardiac in 44 patients (12.1%), of whom
35 deaths (9.5%) were defined as sudden. Kaplan-Meier curves for
the cumulative risk of total mortality in the 25(OH)D quartiles for
patients with a TnT release are presented in Figure 4.
ROC curve for 25(OH)D in patients with a TnT release is
shown in Figure 5. The area under the ROC curve for 25(OH)D
was 0.276 (p,0.0001).
There was a statistically highly significant difference between
each of the upper three quartiles as compared to Q1 of 25(OH)D
Table 2. Baseline characteristics of patients with a TnT
release arranged according to the quartiles of 25(OH)D.
Quartiles of 25(OH)D
Characteristics
n (%) Q1 Q2 Q3 Q4 p-value
25(OH)D (nmol/L)* 28.665.4 42.363.9 55.363.6 73.1614.0 ,0.0001
Age, years* 70.0612.5 65.7611.5 63.2610.8 59.2613.7 ,0.0001
Male, n (%) 48 (49.5) 58 (59.8) 77 (79.4) 75 (77.3) ,0.0001
Smoking status,
n (%)
0.647
Current Smoker,
n (%)
26 (27.4) 28 (29.8) 22 (22.7) 26 (27.1)
Past smoker,
n (%)
51 (53.7) 51 (54.3) 49 (50.5) 48 (50.0)
Never Smoked,
n (%)
18 (18.9) 15 (16.0) 26 (26.8) 22 (22.9)
Angina Pectoris,
n (%)
15 (15.5) 25 (25.8) 29 (29.9) 25 (25.8) 0.111
CHF, n (%)
Killip Class 2–4 29 (29.9) 21 (21.6) 13 (13.4) 22 (22.7) 0.051
History of previous
MI, n (%)
13 (13.4) 15 (15.5) 10 (10.3) 10 (10.3) 0.634
CABG, n (%) 3 (3.1) 9 (9.6) 9 (9.3) 4 (4.2) 0.145
PCI, n (%) 9 (9.3) 12 (12.4) 16 (16.5) 10 (10.3) 0.426
Hypertension,
n (%)
70 (72.2) 63 (64.9) 54 (55.7) 59 (60.8) 0.107
History of DM 1,
n (%)
6 (6.2) 2 (2.2) 1 (1.0) 0 (0.0) 0.026
History of DM 2,
n (%)
39 (40.2) 25 (26.9) 22 (22.7) 13 (13.5) 0.0003
STEMI, n (%) 27 (27.8) 27 (29.7) 24 (24.7) 40 (41.7) 0.060
eGFR (mmol L21)* 72.1636.0 73.8632.3 82.1632.9 73.2629.1 0.126
Cholesterol/Statin,
n (%)
18 (18.6) 21 (21.6) 19 (19.6) 15 (15.5) 0.737
Beta-blocker, n (%) 21 (21.6) 23 (24.5) 31 (32.3) 24 (25.5) 0.383
Known CHD, n (%) 24 (24.7) 40 (41.7) 40 (41.2) 36 (37.1) 0.049
BMI (kg/m2)* 27.664.8 27.364.7 27.963.9 27.763.2 0.810
BNP Quartiles 0.004
Q1 19 (19.6) 17 (17.5) 36 (37.1) 25 (25.8)
Q2 16 (16.5) 28 (28.9) 22 (22.7) 31 (32.0)
Q3 28 (28.9) 25 (25.8) 19 (19.6) 25 (25.8)
Q4 34 (35.1) 27 (27.8) 20 (20.6) 16 (16.5)
hsCRP Quartiles 0.115
Q1 19 (20.0) 21 (21.9) 27 (27.8) 30 (30.9)
Q2 22 (23.2) 23 (24.0) 25 (25.8) 24 (24.7)
Q3 20 (21.1) 25 (26.0) 30 (30.9) 23 (23.7)
Q4 34 (35.8) 27 (28.1) 15 (15.5) 20 (20.6)
*Mean 6 SD.
SD, standard deviation; 25(OH)D, 25-hydroxyvitamin D; CHF, congestive heart
failure; MI, myocardial infarction; CABG, coronary artery bypass grafting; PCI,
percutaneous coronary intervention; DM, diabetes mellitus; STEMI, ST-elevation
myocardial infarction; TnT, troponin T; eGFR, estimated glomerular filtration
rate; CHD, coronary heart disease; BMI, body mass index; BNP, B-type natriuretic
peptide; hsCRP, high sensitivity C-reactive protein.
doi:10.1371/journal.pone.0043228.t002
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in the univariate analysis of all cause mortality, cardiac death and
SCD, respectively.
When comparing 25(OH)D in Q4 to Q1 in a multivariable Cox
regression model for all-cause mortality within 2 years in patients
with TnT release, the HR was 0.24 (95% CI, 0.10–0.54),
p = 0.001. For cardiac death, the HR was 0.18 (95% CI, 0.05–
0.60), p = 0.006, and for SCD, the HR was 0.25 (95% CI, 0.07–
0.89), p = 0.033 (Table 5).
Patients without troponin T release
All-cause mortality, cardiac death and sudden cardiac
death. After a follow-up period of 24 months, 37 patients (6.3%)
of 593 with no TnT release had died. In the univariate analysis of
all-cause mortality in these patients, the HR for 25(OH)D was 0.39
(95% CI, 0.15–1.00), p = 0.05, whereas 25(OH)D status did not
add any prognostic information related to cardiac death and SCD.
Discussion
This prospective observational study was designed to evaluate
the prognostic utility of 25(OH)D in admission samples from
consecutively included chest pain patients with suspected ACS in a
beef-eating population living at a high altitude in a subtropical
inland city of Argentina. We performed a comparative inter-
quartile analysis of 25(OH)D as a prognostic biomarker in the total
population, and in patients with and without TnT release,
respectively.
We have previously confirmed the prognostic value of the
established risk markers BNP and hsCRP in this study population
[19], and in the multivariable analysis of 25(OH)D as a prognostic
indicator we have corrected for these predictors in order to
evaluate its prognostic independency.
After correcting for other possible confounders including
cardiovascular risk factors, the use of medications, age, gender,
BMI and the sampling time, we were able to demonstrate a
statistically significant association between low levels of 25(OH)D
and 2 year survival for total mortality, cardiac death and SCD,
both in the total population and in patients with a TnT release.
Several other markers in addition to 25(OH)D were also found to
predict future mortality, as shown in Tables 4 and 5. Due to the
geographical location close to the Equator and less seasonal
variations as compared to tempered zones, we chose to test for
month of sampling as a potential confounder instead of seasons.
However, applying seasons in our model made no difference.
Several other observational and epidemiological studies have
also shown an inverse association between both all-cause and
Figure 1. Mean 25(OH)D levels by month.
doi:10.1371/journal.pone.0043228.g001
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cardiac mortality and vitamin D. In the NHANSE III study, the
lowest 25(OH)D quartile was associated with a higher risk of all-
cause mortality in the general US population [10] as well as in
older US adults (age .65) [12]. In the general US population, the
CVD mortality showed a similar trend, but did not remain
statistically significant in the fully adjusted model, whereas CVD
mortality was found to be statistically significant in the older US
population. The Tromsø study [9] showed a significantly increased
risk of all-cause death in the lowest 25(OH)D quartile as compared
to the highest in the non-smoking population, whereas 25(OH)D
did not predict CVD outcome. Furthermore, low levels of
25(OH)D were associated with all-cause and cardiovascular
mortality in the LURIC study [7], which included clinically stable
patients referred for coronary angiography. In that population,
patients with low levels of 25(OH)D were found to have a higher
mortality rate due to heart failure and SCD [15]. The
Framingham Offspring Study [6] demonstrated that low levels
of 25(OH)D were associated with higher CVD risk in patients with
hypertension. In the Nurses’ Health Study and the Health
Professionals Follow-Up Study [8] it was suggested that a higher
vitamin D intake correlated with a lower risk of CVD in men but
not in women. In the Mini-Finland Health Survey, Kilkkinen et al.
[5] demonstrated that a low level of 25(OH)D may be associated
with a higher risk of a fatal CVD event. Two other studies suggest
Table 3. Discriminate analysis of all cause mortality using
25(OH)D and their natural logarithm, for the total patient
population and in patients groups with and without TnT
release, respectively.
Population 25(OH)D Log 25(OH)D
Total Specificity 62.2 68.0
Sensitivity 67.2 62.2
Overall 62.8 67.3
p-value ,0.0001 ,0.0001
TnT release Specificity 63.2 69.1
Sensitivity 72.0 67.1
Overall 65.0 68.7
p-value ,0.0001 ,0.0001
No TnT release Specificity 55.8 63.2
Sensitivity 59.5 56.8
Overall 56.0 62.8
p-value 0.018 0.010
25(OH)D, 25-hydroxyvitamin D; TnT, troponin T.
doi:10.1371/journal.pone.0043228.t003
Figure 2. Kaplan-Meier plots for total mortality of 25(OH)D quartiles in the total patient population.
doi:10.1371/journal.pone.0043228.g002
Vitamin D, a Predictor of Mortality in ACS
PLOS ONE | www.plosone.org 6 September 2012 | Volume 7 | Issue 9 | e43228
a higher prevalence of 25(OH)D deficiency in patients with acute
MI [13–14].
In our study, patients were recruited from a subtropical area at
an altitude above 1000 m and included an Hispanic population.
Despite the geographical location there were significant seasonal
changes in 25(OH)D levels. The contribution of diet to vitamin D
status is probably negligible in this population as the intake of fatty
fish, the primary source of vitamin D in the diet, is very low. Also,
the food fortification with vitamin D in Argentina was introduced
at the end of 2010.
Despite the availability of vitamin D through sun exposure, a
high proportion of this population demonstrated subnormal levels
of 25(OH)D, which could be explained by their lifestyle with long
working hours and a siesta in the middle of the day, avoiding the
sun due to the heat. Furthermore, the majority of this population
belonged to an urban and sheltered environment. Although these
patients were living at a high altitude, this altitude would not
promote noteworthy additional exposure to UV radiation.
Patients in Q1 of 25(OH)D would be classified as vitamin D
deficient according to the general agreement. In this quartile, patients
Figure 3. Receiver operated characteristics curve for 25(OH)D related to all-cause mortality in the total patient population.
doi:10.1371/journal.pone.0043228.g003
Table 4. Hazard ratios for 25(OH)D, age, TnT, BNP, hsCRP and
BMI.
Total patient population
Variables All-cause mortality Cardiac Death
Sudden
Cardiac Death
25(OH)D 0.37 (0.19–0.73) 0.23 (0.08–0.67) 0.32 (0.11–0.94)
Age 1.06 (1.04–1.08) 1.05 (1.03–1.08) 1.08 (1.05–1.12)
TnT 2.58 (1.67–4.00) 2.33 (1.29–4.20) 3.17 (1.61–6.22)
BNP 1.97 (1.02–3.81) 2.80 (1.03–7.60) NA
hsCRP 1.76 (1.00–3.11) NA NA
BMI NA NA 1.07 (1.00–1.13)
Values are given as hazard ratio (95% CI).
25(OH)D, 25-hydroxyvitamin D; TnT, troponin T; BNP, B-type natriuretic peptide;
hsCRP, high sensitivity C-reactive protein; BMI, body mass index.
doi:10.1371/journal.pone.0043228.t004
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were older, included more females, had higher rates of DM, heart
failure, hypertension, lower eGFR, and a higher proportion presented
with a TnT release. The lowest quartile also had higher levels of BNP,
hsCRP and less CHD patients. Except for hypertension and eGFR,
similar differences were found in patients with a TnT release, in which
the highest quartile also included more STEMI, with a borderline
significant p-value of 0.06.
In both univariate and multivariate analysis, we demonstrated a
statistically highly significant increase in all-cause mortality,
cardiac and SCD in Q1 as compared to Q4, both in the total
patient population and in patient with a TnT release. After
adjusting for covariates, the prognostic utility of 25(OH)D was
maintained for all end-points.
ROC analysis supports our results related to low 25(OH)D
values and high mortality in the total population (0.307,
p,0.0001) and in the population with TnT release (0.276,
p,0.0001). Although the AUC score in the ROC analysis is low,
the low scores reflect high mortality, as it represents the lower and
not the higher quartile of 25(OH)D values. The opposite relation
would yield a value in the upper half of the ROC.
A strength of this study would be the inclusion of patients with
suspected ACS, collection of blood samples at admission, a
planned sub-group analysis according to TnT release and a
prospective design, evaluating the prognostic value of 25(OH)D in
relation to pre-specified endpoints consisting of total mortality,
cardiac and sudden cardiac death. Furthermore, the study patients
were regularly contacted and only two patients were lost to follow
up. Treatment was based on strict adherence to ACC recom-
mendations [23] at all hospitals and included aspirin, clopidogrel
and statins as secondary preventions and specific management
related to revascularization (usually limited to primary PCI) and to
complications such as arrhythmias and heart insufficiency [19].
Some limitations of this study merit consideration. Concentra-
tions of 25(OH)D in the healthy state prior to hospitalization
remain unknown and our analyses are based on a single baseline
measurement. As patients in our ACS registry were strictly treated
according to ACC guidelines, medication was not recorded
specifically post discharge.
Differentiation of chest pain was usually performed prior to
hospitalization and our patients were included after admission
with a suspected ACS diagnosis. As this is not a randomized study
but a registry with few exclusion criteria limited to age, consent
and prior inclusion, all ACS patients who were asked to
participate, accepted the invitation, except for two subjects. We
cannot provide the exact number of patients who were not asked.
However, in the private hospitals in which 94.5% of the study
population was included, the admission rate was lower than in the
public hospital, and these patients were generally accounted for.
Although we did not adjust for left ventricular ejection fraction,
we did adjust for BNP and known CHF (Killip-Kimball class).
Furthermore, we did not correct for parathyroid hormone.
Figure 4. Kaplan-Meier plots for total mortality of 25(OH)D quartiles in patients with TnT release.
doi:10.1371/journal.pone.0043228.g004
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According to our results, 25(OH)D may serve as a useful
predictor of all-cause and cardiac mortality including SCD.
Randomized controlled trials are needed to evaluate whether ACS
patients may profit therapeutically by vitamin D intervention.
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